Cargando…
The Role of the Kinase Inhibitors in Thyroid Cancers
Thyroid cancer is the most common endocrine malignancy, accounting for about 3% of all cancer cases each year worldwide with increasing incidence, but with the mortality remaining stable at low levels. This contradiction is due to overdiagnosis of indolent neoplasms identified by neck ultrasound scr...
Autores principales: | Cuomo, Francesca, Giani, Claudio, Cobellis, Gilda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143582/ https://www.ncbi.nlm.nih.gov/pubmed/35631627 http://dx.doi.org/10.3390/pharmaceutics14051040 |
Ejemplares similares
-
Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy
por: Cuomo, Francesca, et al.
Publicado: (2019) -
The Possible Role of Cancer Stem Cells in the Resistance to Kinase Inhibitors of Advanced Thyroid Cancer
por: Gianì, Fiorenza, et al.
Publicado: (2020) -
Kinase inhibitors in thyroid cancers
por: Sukrithan, Vineeth, et al.
Publicado: (2023) -
Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
por: Ragusa, Francesca, et al.
Publicado: (2022) -
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)